10.44
0.07 (0.68%)
| Penutupan Terdahulu | 10.37 |
| Buka | 10.56 |
| Jumlah Dagangan | 1,383,320 |
| Purata Dagangan (3B) | 1,153,996 |
| Modal Pasaran | 822,658,496 |
| Harga / Jualan (P/S) | 5.90 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Apr 2026 |
| Margin Operasi (TTM) | -276.53% |
| EPS Cair (TTM) | -5.18 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1,391.60% |
| Nisbah Semasa (MRQ) | 3.58 |
| Aliran Tunai Operasi (OCF TTM) | -282.68 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -201.84 M |
| Pulangan Atas Aset (ROA TTM) | -55.01% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Phathom Pharmaceuticals, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.80 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.28% |
| % Dimiliki oleh Institusi | 84.77% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 31 Dec 2025 | 7,464,572 |
| Carlyle Group Inc. | 31 Dec 2025 | 3,496,808 |
| Ensign Peak Advisors, Inc | 31 Dec 2025 | 2,352,020 |
| Catalys Pacific, Llc | 31 Dec 2025 | 1,429,014 |
| Wasatch Advisors Lp | 31 Dec 2025 | 1,331,669 |
| Julat 52 Minggu | ||
| Median | 25.00 (139.46%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 27 Feb 2026 | 25.00 (139.46%) | Beli | 12.56 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| PARIKH ASIT | 11.11 | 11.11 | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
| Purata Pembelian Keseluruhan ($) | 11.11 | |||
| Purata Jualan Keseluruhan ($) | 11.11 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| PARIKH ASIT | Pengarah | 10 Mar 2026 | Dibuang (-) | 40,000 | 11.11 | 444,400 |
| PARIKH ASIT | Pengarah | 10 Mar 2026 | Diperolehi (+) | 40,000 | 11.11 | 444,400 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 |
| 07 Jan 2026 | Pengumuman | Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants |
| 07 Jan 2026 | Pengumuman | Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants |
| 07 Jan 2026 | Pengumuman | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |